MCM6

Across TCGA pan-cancer cohorts, MCM6 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MCM6’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MCM6 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MCM6 is over-expressed in tumor.

CCRCC, COAD, and LSCC are the cancer types where MCM6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MCM6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+1.318	<.001	12	view →
COAD	Female	All	+0.731	<.001	12	view →
LSCC	Male	II,III,IV	+1.687	<.001	9	view →
LUAD	Male	III,IV	+1.118	<.001	9	view →
HNSC	Male	IV	+0.903	<.001	8	view →
PDAC	Female	All	+0.665	<.001	8	view →
OV	All	All	+0.867	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MCM6–CCRCC

Open the CCRCC breakdown →